Objectives Acute myeloid leukaemia (AML) is an aggressive haematological cancer associated with significant humanistic impact. The current study assessed how the general public in the United Kingdom (UK) values AML health states. Methods The composite time trade-off (cTTO) methodology was employed to elicit health state utilities in AML. Pertinent AML literature related to symptom and quality-of-life impact including physical, functional and emotional well-being, as well as the safety profile of AML treatments, were taken into consideration for drafting health state descriptions. Ten health states included in the study were newly diagnosed AML, induction, consolidation, maintenance, long-term follow-up, relapsed/refractory, stem-cell transplant (SCT) procedure, SCT recovery, SCT long-term follow-up with complications and SCT long-term follow-up without complications. The descriptions were validated by haematologists and nurse specialists for clinical accuracy and completeness. A total of 210 individuals from the general UK population participated in the cTTO interviews. Descriptive statistics were computed for health state utility values. Results The mean age of the participants was 44.0 years (standard deviation [SD] 14.9, range 18-81) and comprised 129 (61.4%) female participants. The utility values ranged from 0.94 (SD 0.13) for SCT long-term follow-up without complications to − 0.21 (SD 0.62) for the SCT procedure. Conclusions The study provides health utilities for a range of AML health states, with the SCT procedure health state being valued worse than death. The utilities obtained in this study can be employed as inputs in cost-effectiveness analyses of AML therapies.
Introduction
Acute myeloid leukaemia (AML) is a genetically heterogeneous malignancy characterized by proliferation and accumulation of myeloid blast cells in the bone marrow, peripheral blood, and lymphoid tissue [1] . About 351,965 new cases of AML were diagnosed in 2012 globally and 265,461 AML-related deaths were reported [2] . There were 3126 new AML cases and 2601 AML-related deaths in 2015 in the United Kingdom (UK) [3] . The goal of AML treatment is to attain remission and avoid relapse using chemotherapeutic agents involving induction, consolidation and salvage therapy (for relapsed or refractory AML) [4] . AML is known to negatively impact quality of life (QOL) among affected individuals [5, 6] , which is pervasive throughout the different stages of treatment.
Patients not only suffer from significant toxicities associated with chemotherapy but also cancer-related fatigue (CRF). AML patients have reported fatigue [7] , anxiety, pain, mobility issues and problems associated with performing usual activities [6] .
Over the past years, the prognostic relevance of QOL has been recognized in certain cancers [8] , including AML [9, 10] . For example, Deschler et al. investigated the prognostic value of QOL assessment among patients with myelodysplastic syndrome (MDS) (a disease that may progress to AML) and AML [10] . It was reported that the patients with impairments in activities of daily living, worse functional status, and greater fatigue have a greater likelihood of having poor outcomes [10] . QOL outcomes associated with oncology treatments are increasingly being recognized as important in treatment decision-making [11] , along with traditional clinical outcomes such as overall survival, progression-free survival, and complete remission. QOL benefits of treatments can be quantified in the form of health state utilities. Utilities represent the strength of an individual's preference for being in a particular health state, quantified into an index value, typically scaled between 0 (death) and 1 (full health) [12] .
There is a significant knowledge gap regarding utilities for different health states in AML. AML health states that have typically been evaluated in economic models include induction chemotherapy, complete remission, relapse, consolidation therapy and transplantation [13] [14] [15] . Studies report utilities for a few AML health states; however, not for the entire spectrum of AML health states [6, [14] [15] [16] [17] . Szende et al. [16] report utilities for three AML health states among pre-leukaemia or MDS patients (mean utility 0.78). In one study among Japanese AML patients, Kurosawa et al. [14] administered a visual analogue scale (VAS) to 35 physicians who were knowledgeable about AML and transplantation to elicit utilities. In elderly AML patients, Uyl-de Groot et al. [15] estimated utilities only for induction treatment. In another study, Leunis and colleagues reported utility values generated using the EuroQoL five-dimensions questionnaire (EQ-5D) for AML patients who achieved complete remission, received allogenic haematopoietic stem cell transplantation (HSCT), and those who received chemotherapy, but not all health states pertaining to AML [6] . In addition, utilities have been estimated by mapping QOL questionnaires onto indirect preference-based questionnaires such as the EQ-5D. For example, Grulke et al. [17] assessed QOL in patients before and after HSCT using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30, which was mapped onto EQ-5D using a pre-established algorithm. Utility values for pre-HSCT, hospitalization for HSCT, up to 6 months post-HSCT and > 1 year after HSCT were reported in their study [17] .
In the absence of published EQ-5D utilities for all relevant AML health states, directly observed or obtained from mapping, we used the time trade-off (TTO) methodology to obtain health state values. TTO was selected as the method of choice for utility elicitation because it is easy for respondents to relate to time, resulting in lower cognitive burden among respondents compared with risk-based utility elicitation methods such as the standard gamble. Further, of the techniques that can be used for utility elicitation, the TTO is the preferred method according to the guidelines of the National Institute for Health and Care Excellence (NICE) in the UK [18] . Members of the general UK public were selected as respondents to align with the study purpose, which was to use utilities to inform the cost-effectiveness analysis conducted from a societal perspective. Utilities for health states can be obtained from members of the general population, patients, patient proxies, or health professionals [19] . There are several arguments about whose preferences (e.g. general population, patients, patient proxies, healthcare professionals) should be used in healthcare resource allocation decisions [19] . It is suggested that there are differences in the way the general public and patients value health outcomes, where patients' valuation may be biased due to their personal experience and potential benefits associated with the health policy decisions [19] . In addition, patients are not likely to have experienced all health states related to a disease and/or treatment and their valuation is likely to be biased for health states that they have experienced in the past.
Therefore, the objective of this research is to determine how members of the general public value various health states associated with AML using the composite TTO (cTTO) methodology. These utility values could be used as inputs to AML decision models and can be used to estimate quality-adjusted life-years (QALYs). These QALYs can be utilized in health technology appraisals (HTAs) of AML treatments to support market access and reimbursement decisions based on clinical and cost effectiveness.
Methods

Overview of cTTO Methodology
The cTTO is a preference elicitation technique used to generate utilities that are employed in health economic evaluations of treatments/interventions. Respondents are provided with a series of choice tasks where they are asked to imagine being in a hypothetical health state for a certain duration (years) and then compare that with being in a health state corresponding to full health for a shorter span of time that they equally value [20] . The duration in the two hypothetical health states is iteratively varied until a point of preferential indifference is achieved.
The cTTO protocol was recently introduced by the EuroQol Group in their EQ-VT protocol for EQ-5D-5L valuation studies and may be considered best practice for conducting cTTO studies, because the cTTO task addresses well known limitations of earlier TTO approaches, is well documented, and has been implemented with quality control (QC) as of EQ-VT version 1.1 [20] [21] [22] [23] . As of version 1.1, the EQ-VT protocol is paired with a QC procedure to review protocol compliance and interviewer effects while the study is ongoing. The QC report flags interviews as being of potentially poor quality based on certain criteria. The cTTO task was completed in a computer-assisted personal interview, and the incoming interview data were continuously monitored to provide the interviewers with feedback on their performance. The interview tool was built in MS PowerPoint and reviewed for correct implementation of the task. The tool stored the elicited TTO values together with paradata required for QC of the data, as explained by Ramos-Goñi et al. [22] . Briefly, the cTTO uses the conventional TTO task for the valuation of better-than-dead states, and lead time TTO for the valuation of states worse than dead (WTD). Thus, for each health state, participants were asked to state whether they would prefer to live in the health state described for 10 years, followed by death, or whether they would rather have a life in full health for shorter duration t. The value for t was varied until the point of indifference was found, where the participant was unable to choose.
When participants preferred immediate death to living in a health state for 10 years, the cTTO task was completed using a slightly different question, involving choices between a short life comprised of t years in full health, and a longer life with 10 years in full health followed by 10 years in the disease state (for a combined duration of 20 years). Again, t was varied to find the point of indifference among these choices. This method therefore allows negative utility values.
Development of Health State Descriptions
Health state descriptions that were evaluated during the cTTO interviews were developed based on published literature related to the symptom and humanistic burden [24] in AML [6, 25] , the existing treatment paradigm in AML [26] , cTTO methodology guidance [20] and its application in oncology. An iterative approach was undertaken in the development of health state descriptions to ensure clinical relevance, clarity and comprehensibility for all study participants. Relevant elements of AML symptoms and aspects of physical, functional, emotional and well-being were incorporated in the descriptions. In addition, key adverse events reported in clinical trials were also included in the health state descriptions. Literature review was an ongoing process throughout the course of health state development [27] .
The draft health state descriptions were reviewed with key opinion leaders in the field of AML and the research team and iteratively revised based on the inputs received. The final health states developed and evaluated in this study were (i) newly diagnosed, (ii) induction, (iii) consolidation, (iv) maintenance, (v) long-term follow-up > 1 year, (vi) treatment failure/relapse/refractory, (vii) stem-cell transplant (SCT) procedure, (viii) SCT recovery < 1 year, (ix) longterm follow-up after SCT > 1 year without complications and (x) long-term follow-up after SCT > 1 year with graftversus-host disease (GVHD).
Validation of Health State Descriptions
To ensure their clinical accuracy and completeness, the health state descriptions were validated by two consultant haematologists (one from the UK and one from Canada), two clinical nurse specialists (both from the UK), and two AML patients. During this process, the clinicians, nurses, and patients were provided with the health state descriptions and were asked to give feedback via individual phone interviews/email on whether the signs or symptoms of AML were correctly captured and whether the health states descriptions were accurate, and vignette equivalence (VE) was tested. The descriptions were revised based on their feedback. Final health state descriptions utilized in this study can be found in an appendix (see electronic supplementary material).
Two hundred and twenty individuals among the general population in the UK were recruited in order to complete the cTTO questionnaires in person via individual face-to-face interviews conducted by three trained interviewers. Written and verbal descriptions of the exercise, and instructions on how to complete the cTTO questionnaire, were provided to participants in each interview session. Participants were first asked to complete a set of standard demographic questions and then asked to rate the health states for AML. Approximately 45 min was estimated for interviews to provide instructions and for participants to complete the survey.
Quality Control and Outcomes
Quality control (QC) of the interviews was a continuous process as per the recommended QC process for EQ-5D-5L valuation studies [22] .
Further, number of interviews with at least one WTD utility value, number of interviews without WTD value, but 0 utility as the bottom value for one or more health state, and the number of interviews with WTD values where the interviewee assigned a − 1 utility value to one or more health state were calculated. It was ascertained that the interviewers met the quality requirements.
The key outcome of interest in this study was a utility value for each health state examined. Because we considered it appropriate to incorporate the utility values elicited from respondents only if they understood the assignment, we used exclusion criteria in line with common practice [28] . Responses were excluded (i) if a participant clearly did not understand the task (indicated by the interviewer) and (ii) if a participant gave the same value to all health states.
Analysis
Descriptive statistics were used to summarise the utility values and describe the sample in terms of key characteristics. Mean and standard deviation (SD) and median and interquartile range (IQR) were used for continuous variables and frequencies and percentages were used for categorical variables. Study responses were analysed descriptively to determine average time to completion and the difference in value between health states.
Results
Out of the 220 participants recruited for the interviews, 212 participated in the interviews. Two interviewees did not comprehend the tasks and were excluded from analysis, resulting in 210 participant interviews finally included in the analysis. The sample size rested on the consideration that a sample size of > 200 will comprise a sufficiently large number of each type of respondent (with and without WTD preference) to consider the resulting values reliable. Table 1 provides the demographic characteristics of the study respondents (n = 210). The mean age of the study sample was 44.0 years (SD 14.9), with 61.4% female participants. A quarter of the participants were in the age group 45-54 years (25.2%). Sixty percent of the study participants had at least secondary education, and 72.9% were working at the time of the interviews. The demographic distribution of the study sample is similar to, but slightly younger and with more females, than the general population in the UK [29].
Main Attributes of Survey Participants (or Respondents)
Quality of Interviews
Quality checks of the interviews were conducted and resulted in the following outcomes: on average, the interviews lasted for 30.3 min (SD 6.65). There were only two interviews during which the example exercises lasted < 3 min. There were no interview sessions with total time spent on all AML 
Descriptive Statistics: Utility Values
The descriptive statistics related to utilities for all health states examined in this study are reported in Table 2 . According to the respondents, 'SCT procedure' was considered as WTD, and was valued as the worst of all the health states evaluated, with an estimated utility of − 0.21. On the other hand, 'long-term follow-up after SCT > 1 year without complications' was valued as the best state of those examined in this study, with an estimated utility of 0.94.
Discussion
This study used the cTTO method to evaluate individual preferences for different health states of AML using a sample from the general UK population. The health state development process included qualitative interviews with consultant haematologists, clinical nurses and patients with AML, highlighting the relevance of including qualitative methods to inform economic models [30] . As a result, the health state descriptions captured important elements of the clinical nature of the disease as well as patient experience. Existing NICE guidance for valuing health states refers to the measurement and valuation of health (MVH) protocol for conducting TTO studies [18] . However, this guidance was produced in 2011 and has not been updated since to consider progressing insights. The EQ-VT protocol followed in this study implements improved methods for valuing states that subjects consider WTD and also benefits from other knowledge gain in the two decades since the first use of the MVH protocol [20] . This EQ-VT protocol is widely considered to represent best practice now. The EQ-VT and MVH protocols for TTO use the same approach for valuation of states better than dead. The EQ-VT protocol, however, has replaced the WTD task of the MVH protocol with lead-time TTO. The reasons for this have been described by Oppe et al. [20] . It is important to consider how the EQ-VT protocol has evolved where researchers realized the need to monitor interviewer performance during TTO data collection to enable timely intervention if problems are detected. The EQ-VT protocol has been implemented with a QC procedure, as recommended, to minimize interviewer effects and maximize data quality. As of version 1.1, the EQ-VT protocol is paired with a QC procedure to review protocol compliance and interviewer effects while the study is ongoing. A QC report flags interviews as being of potentially poor quality. Furthermore, a checklist for cTTO studies published by the EuroQoL group, which incorporates a list of choices to be made by researchers who wish to perform a cTTO task, was followed to ensure appropriate methodology for this study [28] .
The cTTO values in this study ranged from 0.94 for the mildest state (SCT long-term follow-up without complications) to − 0.21 for the worst AML state (SCT procedure). To our knowledge, there has been no other published study using the cTTO method to evaluate the general UK public's preference of AML health states. Kurosawa et al. [14] used a questionnaire based on a VAS among physicians specializing in haematology to investigate the health utility of several AML health states. While the results of Kurosawa et al. are not directly comparable to those of our study due to the differences in methodology and study population, both studies share similar findings: the health states of 'long-term followup' (either after chemotherapy or after SCT procedure, without GVHD) were considered close to full health (scored 0.9 in the study conducted by Kurosawa et al. and 0.89 [after chemotherapy] and 0.94 [post SCT, without complications] in our study). Furthermore, the utility scores of the health states 'treatment failure/relapse/refractory' and 'long-term follow-up after SCT, with GVHD' were estimated as 0.5 in both studies [14] . Overall, the results of this study reflect the severity of different health states of AML patients along the treatment pathway as perceived by physicians and nurses. For example, induction therapy phase and SCT procedure phase were the least preferred health states by the general population, whilst the maintenance phase, follow-up phase (after chemotherapy) and the long-term follow-up phase after SCT (without complications) were considered close to full health. It is noticeable that the utility score of the health state 'SCT procedure' is negative in our study. As mentioned above, this score can't be directly compared with the scores from other studies, which adopted different methods, such as a questionnaire-based study or a TTO study not allowing the WTD health states [14] .
Participants had the least consensus in terms of their preferences on the two most severe health states (i.e. induction treatment [SD 0.57] and SCT procedure [SD 0.62]). This could be explained by the range in individuals' preference for untoward situations. During the interviews, there were participants who expressed strong aversion towards trading life-years, regardless of the health states description; on the other hand, there were participants who tried to avoid any time spent in poor health states (i.e. score − 1). If the preference values of these health states are to be used in future health economic models, sensitivity analyses around these values are strongly recommended to test their influence on the results.
Besides the worst health states, participants also expressed a wide variation in preference for the health state 'long-term follow-up after SCT > 1 year, with GVHD'. This can be partially explained by the nature of GVHD itself: GVHD is characterized by diverse symptoms with varying levels of severity, which makes it difficult to describe the health state in a simple manner. This might leave a lot of room for participants to interpret the health state description by themselves, and as a consequence have different utility scores.
The results of this study should be interpreted in the light of a few limitations. The sample size of our study was 210 participants and therefore the study was not powered to identify correlations between health state preferences and characteristics of respondents (e.g. age, education level, etc.). However, this sample size is considered reasonable as per cTTO methodology guidance [20] to support a descriptive analysis of health states preference in cTTO studies and fulfil the objectives of this study. A limitation of our study is that the TTO procedure assumed a time horizon of 10 years for all disease states that were valued, while some of the valued health states describe problems of a temporary nature. We considered whether we could address this issue by replacing the standard TTO with a method better suited to the valuation of temporary health states. Several alternate methods have been experimented with to value temporary health states such as those valuated in this study [31, 32] , but unfortunately challenges remain with these alternative methods and their use render comparison with other published values impossible. Hence, we decided to use a standard TTO protocol for all health states. It is unknown how use of an unrealistic time horizon may have affected the values. Therefore, the obtained utilities for temporary health states such as SCT and induction therapy should be interpreted with caution as these states do not last for an extended time period. In addition, specific treatments in AML are not taken into account when developing the health state descriptions. In the event that new therapies with specific side effects are used to treat AML patients, findings of this study should be interpreted with caution. In order to include these health states in an economic model, there is a need to factor in the disutility for the new treatment side effects; however, there is a risk of double counting based on the severity of the side effects under consideration [33] .
Conclusions
In summary, this study reports utilities across a range of AML health states. Overall, the results of this study reflect the perceived severity of different health states of AML patients where the induction therapy phase and the SCT procedure phase were the least preferred health states, while the maintenance phase, the follow-up phase (after chemotherapy) and the long-term follow-up phase after SCT (without complications) were valued close to full health. The utilities obtained in this study can be employed as inputs in costeffectiveness analyses of AML therapies.
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